Drug Profile

Research programme: anticancer therapeutics - A2A Pharmaceuticals

Alternative Names: A2A_O-04

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator A2A Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action Clk dual-specificity kinase modulators; Transcription factor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2025 No recent reports of development identified for preclinical development in Leukaemia in USA
28 Feb 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA
19 Jan 2021 A2A Pharmaceuticals announces intention to submit IND to US FDA for Leukaemia and Solid tumours in the third quarter of 2022 (A2A Pharmaceuticals pipeline, November 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com